Workshop report from the national institutes of health taskforce on the research needs of eosinophil-associated diseases (TREAD)

Bruce S. Bochner, Wendy Book, William W. Busse, Joseph Butterfield, Glenn T. Furuta, Gerald J. Gleich, Amy D. Klion, James J. Lee, Kristin M. Leiferman, Michael Minnicozzi, Redwan Moqbel, Marc E. Rothenberg, Lawrence B. Schwartz, Hans Uwe Simon, Michael E. Wechsler, Peter F. Weller

Research output: Contribution to journalArticle

Abstract

Background: Eosinophils are blood cells that are often found in high numbers in the tissues of allergic conditions and helminthic parasite infections. The pathophysiologic roles that eosinophils may serve in other human "eosinophil-associated" diseases remain obscure. Objective: National Institutes of Health (NIH) Institutes and the Office of Disease Prevention assembled an international taskforce of clinical and basic scientists with the charge to propose and prioritize unmet research needs in eosinophil-associated diseases. Methods: The taskforce used an organ system approach to identify the different and common themes of eosinophil cell involvement in these diseases. In early 2012, a draft document was circulated for review. The document was amended and the prioritizations were set at a NIH-organized workshop in June 2012. Results: The taskforce identified significant research needs. These needs cross disease entities but some are disease specific. There are substantial shortcomings to the various preclinical animal models, as well as significant gaps in our epidemiologic, pathophysiologic, diagnostic, prognostic, and therapeutic knowledge. The taskforce recognized that recent efforts by patient advocacy groups have played instrumental roles in improving the identification and characterization of these disorders. However, communications among the eosinophil-interested communities, for example, governmental funding and regulatory agencies, and industry and clinician scientists need to be more comprehensive. Conclusions: Significant efforts are required to address our knowledge gaps to improve the outcomes of eosinophil-associated diseases. NIH Institutes, other federal agencies, lay organizations, and the pharmaceutical industry should consider the taskforce's recommendations in their future research activities.

Original languageEnglish (US)
Pages (from-to)587-596
Number of pages10
JournalThe Journal of Allergy and Clinical Immunology
Volume130
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

National Institutes of Health (U.S.)
Eosinophils
Education
Research
Patient Advocacy
Parasitic Diseases
Drug Industry
Blood Cells
Industry
Animal Models
Communication
Organizations

Keywords

  • apoptosis
  • Churg-Strauss syndrome
  • coagulopathy
  • discovery
  • Eosinophil
  • fusion oncoproteins
  • hypereosinophilic syndromes
  • research
  • therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Workshop report from the national institutes of health taskforce on the research needs of eosinophil-associated diseases (TREAD). / Bochner, Bruce S.; Book, Wendy; Busse, William W.; Butterfield, Joseph; Furuta, Glenn T.; Gleich, Gerald J.; Klion, Amy D.; Lee, James J.; Leiferman, Kristin M.; Minnicozzi, Michael; Moqbel, Redwan; Rothenberg, Marc E.; Schwartz, Lawrence B.; Simon, Hans Uwe; Wechsler, Michael E.; Weller, Peter F.

In: The Journal of Allergy and Clinical Immunology, Vol. 130, No. 3, 09.2012, p. 587-596.

Research output: Contribution to journalArticle

Bochner, BS, Book, W, Busse, WW, Butterfield, J, Furuta, GT, Gleich, GJ, Klion, AD, Lee, JJ, Leiferman, KM, Minnicozzi, M, Moqbel, R, Rothenberg, ME, Schwartz, LB, Simon, HU, Wechsler, ME & Weller, PF 2012, 'Workshop report from the national institutes of health taskforce on the research needs of eosinophil-associated diseases (TREAD)', The Journal of Allergy and Clinical Immunology, vol. 130, no. 3, pp. 587-596. https://doi.org/10.1016/j.jaci.2012.07.024
Bochner, Bruce S. ; Book, Wendy ; Busse, William W. ; Butterfield, Joseph ; Furuta, Glenn T. ; Gleich, Gerald J. ; Klion, Amy D. ; Lee, James J. ; Leiferman, Kristin M. ; Minnicozzi, Michael ; Moqbel, Redwan ; Rothenberg, Marc E. ; Schwartz, Lawrence B. ; Simon, Hans Uwe ; Wechsler, Michael E. ; Weller, Peter F. / Workshop report from the national institutes of health taskforce on the research needs of eosinophil-associated diseases (TREAD). In: The Journal of Allergy and Clinical Immunology. 2012 ; Vol. 130, No. 3. pp. 587-596.
@article{6d1d606105e841dca860771b9876720b,
title = "Workshop report from the national institutes of health taskforce on the research needs of eosinophil-associated diseases (TREAD)",
abstract = "Background: Eosinophils are blood cells that are often found in high numbers in the tissues of allergic conditions and helminthic parasite infections. The pathophysiologic roles that eosinophils may serve in other human {"}eosinophil-associated{"} diseases remain obscure. Objective: National Institutes of Health (NIH) Institutes and the Office of Disease Prevention assembled an international taskforce of clinical and basic scientists with the charge to propose and prioritize unmet research needs in eosinophil-associated diseases. Methods: The taskforce used an organ system approach to identify the different and common themes of eosinophil cell involvement in these diseases. In early 2012, a draft document was circulated for review. The document was amended and the prioritizations were set at a NIH-organized workshop in June 2012. Results: The taskforce identified significant research needs. These needs cross disease entities but some are disease specific. There are substantial shortcomings to the various preclinical animal models, as well as significant gaps in our epidemiologic, pathophysiologic, diagnostic, prognostic, and therapeutic knowledge. The taskforce recognized that recent efforts by patient advocacy groups have played instrumental roles in improving the identification and characterization of these disorders. However, communications among the eosinophil-interested communities, for example, governmental funding and regulatory agencies, and industry and clinician scientists need to be more comprehensive. Conclusions: Significant efforts are required to address our knowledge gaps to improve the outcomes of eosinophil-associated diseases. NIH Institutes, other federal agencies, lay organizations, and the pharmaceutical industry should consider the taskforce's recommendations in their future research activities.",
keywords = "apoptosis, Churg-Strauss syndrome, coagulopathy, discovery, Eosinophil, fusion oncoproteins, hypereosinophilic syndromes, research, therapeutics",
author = "Bochner, {Bruce S.} and Wendy Book and Busse, {William W.} and Joseph Butterfield and Furuta, {Glenn T.} and Gleich, {Gerald J.} and Klion, {Amy D.} and Lee, {James J.} and Leiferman, {Kristin M.} and Michael Minnicozzi and Redwan Moqbel and Rothenberg, {Marc E.} and Schwartz, {Lawrence B.} and Simon, {Hans Uwe} and Wechsler, {Michael E.} and Weller, {Peter F.}",
year = "2012",
month = "9",
doi = "10.1016/j.jaci.2012.07.024",
language = "English (US)",
volume = "130",
pages = "587--596",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Workshop report from the national institutes of health taskforce on the research needs of eosinophil-associated diseases (TREAD)

AU - Bochner, Bruce S.

AU - Book, Wendy

AU - Busse, William W.

AU - Butterfield, Joseph

AU - Furuta, Glenn T.

AU - Gleich, Gerald J.

AU - Klion, Amy D.

AU - Lee, James J.

AU - Leiferman, Kristin M.

AU - Minnicozzi, Michael

AU - Moqbel, Redwan

AU - Rothenberg, Marc E.

AU - Schwartz, Lawrence B.

AU - Simon, Hans Uwe

AU - Wechsler, Michael E.

AU - Weller, Peter F.

PY - 2012/9

Y1 - 2012/9

N2 - Background: Eosinophils are blood cells that are often found in high numbers in the tissues of allergic conditions and helminthic parasite infections. The pathophysiologic roles that eosinophils may serve in other human "eosinophil-associated" diseases remain obscure. Objective: National Institutes of Health (NIH) Institutes and the Office of Disease Prevention assembled an international taskforce of clinical and basic scientists with the charge to propose and prioritize unmet research needs in eosinophil-associated diseases. Methods: The taskforce used an organ system approach to identify the different and common themes of eosinophil cell involvement in these diseases. In early 2012, a draft document was circulated for review. The document was amended and the prioritizations were set at a NIH-organized workshop in June 2012. Results: The taskforce identified significant research needs. These needs cross disease entities but some are disease specific. There are substantial shortcomings to the various preclinical animal models, as well as significant gaps in our epidemiologic, pathophysiologic, diagnostic, prognostic, and therapeutic knowledge. The taskforce recognized that recent efforts by patient advocacy groups have played instrumental roles in improving the identification and characterization of these disorders. However, communications among the eosinophil-interested communities, for example, governmental funding and regulatory agencies, and industry and clinician scientists need to be more comprehensive. Conclusions: Significant efforts are required to address our knowledge gaps to improve the outcomes of eosinophil-associated diseases. NIH Institutes, other federal agencies, lay organizations, and the pharmaceutical industry should consider the taskforce's recommendations in their future research activities.

AB - Background: Eosinophils are blood cells that are often found in high numbers in the tissues of allergic conditions and helminthic parasite infections. The pathophysiologic roles that eosinophils may serve in other human "eosinophil-associated" diseases remain obscure. Objective: National Institutes of Health (NIH) Institutes and the Office of Disease Prevention assembled an international taskforce of clinical and basic scientists with the charge to propose and prioritize unmet research needs in eosinophil-associated diseases. Methods: The taskforce used an organ system approach to identify the different and common themes of eosinophil cell involvement in these diseases. In early 2012, a draft document was circulated for review. The document was amended and the prioritizations were set at a NIH-organized workshop in June 2012. Results: The taskforce identified significant research needs. These needs cross disease entities but some are disease specific. There are substantial shortcomings to the various preclinical animal models, as well as significant gaps in our epidemiologic, pathophysiologic, diagnostic, prognostic, and therapeutic knowledge. The taskforce recognized that recent efforts by patient advocacy groups have played instrumental roles in improving the identification and characterization of these disorders. However, communications among the eosinophil-interested communities, for example, governmental funding and regulatory agencies, and industry and clinician scientists need to be more comprehensive. Conclusions: Significant efforts are required to address our knowledge gaps to improve the outcomes of eosinophil-associated diseases. NIH Institutes, other federal agencies, lay organizations, and the pharmaceutical industry should consider the taskforce's recommendations in their future research activities.

KW - apoptosis

KW - Churg-Strauss syndrome

KW - coagulopathy

KW - discovery

KW - Eosinophil

KW - fusion oncoproteins

KW - hypereosinophilic syndromes

KW - research

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84865691348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865691348&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2012.07.024

DO - 10.1016/j.jaci.2012.07.024

M3 - Article

C2 - 22935587

AN - SCOPUS:84865691348

VL - 130

SP - 587

EP - 596

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -